Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First ...

India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 ...

Empagliflozin, which in addition to treating type-2 diabetes, also aids weight loss, and reduces cardiovascular and kidney risks, holds significant promise for volume growth as it becomes more ...

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed ...

By introducing Empagliflozin at INR 5.49 per tablet for ... API raw material which is DMF grade,” he informed. The kind of, molecule, the API when we export is being used, the same has been ...

Alkem Laboratories Ltd on Wednesday announced the launch of generic empagliflozin and its combinations in India. The formulation will launched under the brand name ‘Empanorm’ at prices that ...

Jardiance (empagliflozin) can cause side effects that range from mild to serious. More common side effects include urinary tract infections and genital yeast infections. If side effects from ...

Now, researchers from Stanford Medicine have identified a naturally occurring molecule that mimics semaglutide’s effects but appears to avoid these drawbacks in a study recently published in Nature.

The diabetes care landscape in India is set for a major transformation as domestic pharmaceutical companies reportedly prepare to launch low-cost generic versions of Empagliflozin. The move comes ...

Indian drug companies are set to revolutionize diabetes treatment with affordable generic versions of Empagliflozin, following the expiry of its patent. Estimated to significantly cut costs and ...

Empagliflozin improved clinical outcomes in patients with acute heart failure (AHF), regardless of blood pressure (BP) levels, with particularly strong benefits observed in those with diastolic BP ...